AHO0222

antibody from Invitrogen Antibodies

Targeting: BCL2L1 Bcl-X, bcl-xL, bcl-xS, BCL2L, BCLX, PPP1R52

Provider product page for AHO0222

Western blot

Immunocytochemistry

Immunohistochemistry

Other assay

Antibody data

Antibody Data
Antigen structure
References [9]
Comments [0]
Validations
Western blot [2]
Immunocytochemistry [1]
Immunohistochemistry [1]
Other assay [2]

Submit

Product number: AHO0222 - Provider product page
Provider: Invitrogen Antibodies
Product name: Bcl-X Monoclonal Antibody (2H12)
Antibody type: Monoclonal
Antigen: Synthetic peptide
Description: This antibody reacts with both Bcl-XS (short) and Bcl-XL (long) proteins. The immunogenic sequence (aa 3-14) is conserved in human and mice.
Antibody clone number: 2H12
Concentration: 0.2 mg/mL

BCL2L1 protein structure - AHO0222 shown in red.

Submitted references Induction of apoptosis and suppression of tumor growth by Nur77-derived Bcl-2 converting peptide in chemoresistant lung cancer cells.

Pearce MC, Gamble JT, Kopparapu PR, O'Donnell EF, Mueller MJ, Jang HS, Greenwood JA, Satterthwait AC, Tanguay RL, Zhang XK, Kolluri SK
Oncotarget 2018 May 25;9(40):26072-26085

Immunohistochemical markers of tissue injury in biopsies with transplant glomerulitis.

Batal I, Azzi J, El-Haddad N, Riella LV, Lunz JG 3rd, Zeevi A, Sasatomi E, Basu A, Tan H, Shapiro R, Randhawa P
Human pathology 2012 Jan;43(1):69-80

Beclin 1-independent autophagy induced by a Bcl-XL/Bcl-2 targeting compound, Z18.

Tian S, Lin J, Jun Zhou J, Wang X, Li Y, Ren X, Yu W, Zhong W, Xiao J, Sheng F, Chen Y, Jin C, Li S, Zheng Z, Xia B
Autophagy 2010 Nov;6(8):1032-41

Molecular prognosticators of complex karyotype soft tissue sarcoma outcome: a tissue microarray-based study.

Lahat G, Tuvin D, Wei C, Wang WL, Pollock RE, Anaya DA, Bekele BN, Corely L, Lazar AJ, Pisters PW, Lev D
Annals of oncology : official journal of the European Society for Medical Oncology 2010 May;21(5):1112-20

Clinical and immunohistochemical features associated with a response to bortezomib in patients with multiple myeloma.

Dawson MA, Opat SS, Taouk Y, Donovan M, Zammit M, Monaghan K, Horvath N, Roberts AW, Prince HM, Hertzberg M, McLean CA, Spencer A
Clinical cancer research : an official journal of the American Association for Cancer Research 2009 Jan 15;15(2):714-22

Bcl-x(S) induces an NGF-inhibitable cytochrome c release.

Lindenboim L, Schlipf S, Kaufmann T, Borner C, Stein R
Experimental cell research 2004 Jul 15;297(2):392-403

Essential role of the voltage-dependent anion channel (VDAC) in mitochondrial permeability transition pore opening and cytochrome c release induced by arsenic trioxide.

Zheng Y, Shi Y, Tian C, Jiang C, Jin H, Chen J, Almasan A, Tang H, Chen Q
Oncogene 2004 Feb 12;23(6):1239-47

Differential expression of bcl-2 family proteins in bladder carcinomas. Relationship with apoptotic rate and survival.

Korkolopoulou P, Lazaris ACh, Konstantinidou AE, Kavantzas N, Patsouris E, Christodoulou P, Thomas-Tsagli E, Davaris P
European urology 2002 Mar;41(3):274-83

Differential expression of bcl-2 family proteins in bladder carcinomas. Relationship with apoptotic rate and survival.

Korkolopoulou P, Lazaris ACh, Konstantinidou AE, Kavantzas N, Patsouris E, Christodoulou P, Thomas-Tsagli E, Davaris P
European urology 2002 Mar;41(3):274-83

No comments: Submit comment

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Western blot data of CEM cell extracts incubated with mouse anti-Bcl-XL.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Western blot analysis of Bcl-X was performed by loading 20 µg of Jurkat (lane1), Raji (lane2), A549 (lane3), A431 (lane4) and Cos-7 (lane4) cell lysate using NuPAGE® 4-12 % Bis-Tris gel (Product # NP0322BOX), XCell SureLock™ Electrophoresis System (Product # EI0002), Novex® Sharp Pre-Stained Protein Standard (LC5800), and iBlot® Dry Blotting System (IB21001). Proteins were transferred to a nitrocellulose membrane and blocked with 5 % skim milk for 1 hour at room temperature. Bcl-X was detected at ~ 27 kDa using Bcl-X Mouse Monoclonal Antibody (Product # AHO0222) at 1:1000 in 5 % skim milk at 4°C overnight on a rocking platform. Goat Anti-Mouse - HRP Secondary Antibody (Product # 62-6520) at 1:4000 dilution was used and chemiluminescent detection was performed using Pierce™ ECL Western Blotting Substrate (Product # 32106).

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Immunofluorescent analysis of Bcl-X Antibody was done on 70% confluent log phase A549 cells. The cells were fixed with 4% paraformaldehyde for 15 minutes, permeabilized with 0.25% Triton™ X-100 for 10 minutes, and blocked with 5% BSA for 1 hour at room temperature. The cells were labeled with Bcl-X Antibody (Product # AHO0222) at 1µg/mL in 1% BSA and incubated for 3 hours at room temperature and then labeled with Alexa Fluor 488 Rabbit Anti-Mouse IgG Secondary Antibody (Product # A-11059) at a dilution of 1:400 for 45 minutes at room temperature (Panel a: green). Nuclei (Panel b: blue) were stained with SlowFade® Gold Antifade Mountant with DAPI (Product # S36938). F-actin (Panel c: red) was stained with Alexa Fluor 594 Phalloidin (Product # A12381). Panel d is a merged image showing cytoplasmic and nuclear localization. Panel e is a no primary antibody control. The images were captured at 40X magnification.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Immunohistochemical analysis of Bcl-Xl in formalin-fixed, paraffin-embedded human Hodgkins lymphoma using a Bcl-Xl monoclonal antibody (Product # AHO0222). Detection was performed with a peroxidase-conjugate and AEC chromogen. Note cell membrane staining of Reedternberg cells.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: NULL

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Figure 2 Paclitaxel resistant H460 cells express elevated levels of Bcl-2 (A) Increased Bcl-2 expression in Paclitaxel resistant H460 cells. Western blot analysis of H460 parental and derived paclitaxel resistant cells. (B) High Bcl-2 expression in multidrug resistant H69AR and paclitaxel resistant H460 cells compared to parental H460 cells. Western blot analysis of multidrug resistant H69AR and H460 parental and paclitaxel resistant cells probed with indicated antibodies. (C) Increased phosphorylation of Bcl-2 at serine 70 in H460 paclitaxel resistant cells. Western blot analysis of H460 parental and paclitaxel resistant cells blotted with indicated antibodies. (D) Correlation of high Bcl-2 and increased resistance to paclitaxel. Western blot analysis of H460 parental and paclitaxel resistant cells treated with paclitaxel for 48 hours and probed with indicated antibodies. (E) Analysis of Bcl-2, Mcl-1 and Bcl-xL mRNA levels in parental and resistant H460 cells using quantitative real-time PCR. (F) Bcl-2 protein stability is not altered in parental and paclitaxel resistant cells. The level of Bcl-2 was detected by Western blot and GAPDH was used as a loading control. (G) Bcl-2 expression alone confers resistance to paclitaxel. Flow cytometry-based analysis of viability in H460 parental cells expressing Bcl-2 or control vector, after treatment with 100 nM paclitaxel for 48 hours; right panel: Western blot analysis of transfected cells show increased Bcl-2 expre